Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.09 USD | +7.92% | -5.22% | +98.18% |
Financials (USD)
Sales 2024 * | 7.5M | Sales 2025 * | 18.75M | Capitalization | 37.57M |
---|---|---|---|---|---|
Net income 2024 * | -67M | Net income 2025 * | -72M | EV / Sales 2024 * | -21.2 x |
Net cash position 2024 * | 196M | Net cash position 2025 * | 302M | EV / Sales 2025 * | -14.1 x |
P/E ratio 2024 * |
-0.67
x | P/E ratio 2025 * |
-0.9
x | Employees | 73 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 68.09% |
Latest transcript on Xilio Therapeutics, Inc.
1 day | +7.92% | ||
1 week | -5.22% | ||
Current month | +0.93% | ||
1 month | +65.33% | ||
3 months | +67.69% | ||
6 months | -47.60% | ||
Current year | +98.18% |
Managers | Title | Age | Since |
---|---|---|---|
René Russo
CEO | Chief Executive Officer | 49 | 19-05-21 |
Kevin Brennan
DFI | Director of Finance/CFO | 54 | - |
Chief Tech/Sci/R&D Officer | - | 22-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Clancy
CHM | Chairman | 62 | 20-07-22 |
Daniel Curran
BRD | Director/Board Member | 57 | 20-11-30 |
Tomas Jan Heyman
BRD | Director/Board Member | 68 | 22-09-14 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 1.09 | +7.92% | 144,163 |
24-04-25 | 1.01 | -4.72% | 239,428 |
24-04-24 | 1.06 | +0.95% | 297,031 |
24-04-23 | 1.05 | -4.55% | 448,445 |
24-04-22 | 1.1 | -4.35% | 256,328 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+98.18% | 37.57M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- XLO Stock